From The V Foundation for Cancer Research, "Pathway-Informed Targeted Therapy in Chronic Myelomonocytic Leukemia"... Read More
Expertise in the Study of Leukemia
The Deininger/O'Hare lab expertise is in the study of leukemia. The lab's research program focuses on the biology of myeloproliferative neoplasms and the development of molecularly targeted therapies. We are especially interested in understanding the molecular mechanisms of resistance to tyrosine kinase inhibitors such as imatinib, a drug used to treat chronic myeloid leukemia and some other types of cancer.Now seeking post-doctoral scholar. Apply here.
News & Blog
Michael Deininger, MD, PhD, a Huntsman Cancer Institute (HCI) investigator and professor of internal medicine at the University of Utah, has been listed among the world’s Highly Cited Researchers in 2014 by Thomson Reuters, an international media firm. The list includes more than 3,000 authors worldwide in 21 science and social science fields, representing the top 1% of authors most cited in their specialty areas for the years 2002 to 2012.... Read More
Dr. Deininger named "Highly Cited Researcher" by Thomson Reuters, 2014-2015... Read More
Researchers at HCI have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML).... Read More